But current methods remain challenging. Dr. Amir Jahanian-Najafabadi from Constructor University has been conducting a series of studies exploring the use of advanced computational models applied on ...

Depression and anxiety affect approximately 40% of adults with chronic pain, according to a massive new systematic review and ...

BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers ...

The interplay between cortisol, inflammation, and disease underscores the need for effective stress management to enhance ...

A novel analysis of more than 375 published studies concluded that the association between chronic pain and rates of depression and anxiety is ...

BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the ...

Utah lawmakers unanimously voted to pass SB266 during the 2024 legislative session, a bill legalizing psychedelic dosing for ...

Me, once valued at $6 billion, is now a penny stock. Layoffs, data breaches, and resignations led to its downfall. How did it ...

However, not everyone finds it easy to fulfill the third pillar of Islam – fasting during the month of Ramadan – especially ...

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces the appointment of Pierandrea Muglia, M.D., as Chief Medical Officer. Dr. Muglia brings more than 30 years of experie ...

Axsome Therapeutics (NASDAQ: AXSM) recently received a number of ratings updates from brokerages and research firms: 3/6/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at HC ...

Biohaven (NYSE:BHVN – Free Report) had its price objective lowered by Morgan Stanley from $69.00 to $63.00 in a research note released on Friday,Benzinga reports. The brokerage currently has an ...